跳至主要内容
临床试验/NCT03292744
NCT03292744Unknown4 期

Effect of Alfacalcidol Supplementation to Respiratory Infection, Inflammatory Markers and CD4/CD8 Ratio of Indonesian Elderly

Indonesia University1 个研究点 分布在 1 个国家目标入组 110 人开始时间: 2017年1月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
110
试验地点
1
主要终点
upper respiratory tract infection incidence

研究概览

简要总结

Vitamin D has been known to influence immune response through Vitamin D Receptor in Immune Cells, but only few has been known about the effect alfacalcidol, a vitamin D analog to immune system. In elderly, immune disregulation or immunosenecence have great impact to infection response. This study is aimed to determine the effect of alfacalcidol supplementation in vitro and in vivo to respiratory infection incidence and inflammatory markers, as well as T cell lymphocyte subset in Indonesian elderly patients.

详细描述

This study consist of 2 designs. First is in vitro study to investigate the effect of alfacalcidol supplementation to IL-6, IL-10 and IFN gamma regulation in Peripheral Blood Mononuclear Cells (PBMC) of elderly and second design is randomised controlled trial to evaluate the effect of 3 months supplementation of alfacalcidol 0,5 mcg in respiratory infection, antibiotic use, inflammatory markers, CD4/CD8 ratio and CD8+ CD28+ in Indonesian elderly with various level of frailty syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
60 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Elderly age more than 60
  • Willing to join research

排除标准

  • In acute infection
  • Using NSAID or steroid
  • Liver failure
  • Hypercalcemia

研究组 & 干预措施

Alfacalcidol

Experimental

Alfacalcidol 0,5 mcg once daily for 90 days

干预措施: Alfacalcidol (Drug)

Placebo

Placebo Comparator

Amylum same capsule form, weight and colour with treatment arm

干预措施: Alfacalcidol (Drug)

结局指标

主要结局

upper respiratory tract infection incidence

时间窗: 90 days

incidence of URTI

lower respiratory tract infection incidence

时间窗: 90 days

incidence of LRTI

次要结局

  • inflammatory markers(day 90)
  • antibiotic use(90 days)
  • T cell subset(day 90)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Aulia Rizka

MD

Indonesia University

研究点 (1)

Loading locations...

相似试验